
Shares in AstraZeneca AZN.L rose 2.9% to 10,404p, second top gainer on FTSE bluechip .FTSE index
British drugmaker's CEO Pascal Soriot is considering moving market listing to U.S., the Times reports, citing sources
Report adds CEO was likely to face resistance from parts of board should he push for such a move, as well as the British government, according to sources
AZN declined to comment on the Times report
Stock down under 1% so far this year